Table 1.
Baseline characteristics and clinical data
| Variable | All subjects | Stable group | Progression group | P-value |
|---|---|---|---|---|
| (n = 49) | (n = 32) | (n = 17) | ||
| Sex M/F (n) | 38/11 | 24/8 | 14/3 | 0.56 |
| Age (yr) | 69 (65–75) | 70 (66–76) | 68 (64–75) | 0.38 |
| Smokers/never-smokers (n) | 36/13 | 23/9 | 13/4 | 0.73 |
| Pack-years smoking | 30 (0.8–51.5) | 34 (5–52.1) | 25 (0.8–49.5) | 0.61 |
| BMI | 23.8 (22.1–25.8) | 23.6 (22.1–25.5) | 25.0 (21.7–26.1) | 0.43 |
| GAP stage (n), I/II/III | 20/24/5 | 14/15/3 | 6/9/2 | 0.84 |
| FVC (L) | 2.42 (2.08–2.86) | 2.40 (2.09–3.65) | 2.64 (2.02–2.78) | 0.83 |
| % FVC (%) | 76.6 (65.4–92.5) | 77.4 (65.1–94.4) | 76.6 (66.4–86.9) | 0.78 |
| DLco (mL/min/mmHg) | 10.7 (9.22–13.5) | 10.6 (9.25–13.5) | 10.7 (8.81–14.3) | 0.76 |
| % DLco (%) | 52.8 (44.3–59.8) | 52.8 (44.4–57.6) | 51.7 (43.6–70.3) | 0.97 |
| PaO2 at rest (Torr) | 82.7 (78.2–88.6) | 81.5 (77.2–91.6) | 83.8 (78.4–87.3) | 0.71 |
| Minimum SpO2 during 6MWT (%) | 91 (87.3–93) | 91 (88–93) | 90 (85.5–93) | 0.42 |
| 6MWT Distance (meter) | 410 (380–480) | 420 (385–480) | 400 (360–490) | 0.94 |
| SP-A (ng/mL) | 57.8 (41.7–79.1) | 60.3 (42.6–76.1) | 56.6 (40.6–96.7) | 0.83 |
| SP-D (ng/mL) | 243 (181–352) | 241 (177–357) | 246 (166–350) | 0.97 |
| KL-6 (U/mL) | 901 (663–1494) | 885 (595.3–1618) | 901 (732–1336) | 0.44 |
| pirfenidone/nintedanib | 23/26 | 17/15 | 6/11 | 0.23 |
| Treatment history of anti-fibrotic drug (n), yes/no | 7/42 | 4/28 | 3/14 | 0.66 |
Data are expressed as frequencies or medians (interquartile range). P-value: stable group vs. progression group.
BMI body mass index; GAP (gender [G], age [A], and 2 lung physiology variables [P] [FVC and DLco]); FVC forced vital capacity; DLco diffusing capacity of the lung for carbon monoxide; PaO2 partial pressure of arterial oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6 min-walk test; SP surfactant protein; KL-6 Krebs von den Lungen-6